Acer Medical

What Acer Medical does

Acer Medical Inc. (宏碁智醫股份有限公司) is a Taipei-based, privately held subsidiary of the Acer Group that develops AI-driven medical device software and hardware for healthcare providers, with primary operations across Taiwan and Southeast Asia. Founded on April 25, 2018, the company builds a portfolio of Software as a Medical Device (SaMD) products centered on the VeriSee suite — deep-learning computer vision models that screen color fundus photographs for diabetic retinopathy (VeriSee DR), age-related macular degeneration (VeriSee AMD), and glaucoma (VeriSee GLC), plus VeriOsteo OP, which predicts bone mineral density from chest X-rays. The company complements its imaging AI with aiMed, a generative-AI voice assistant that converts clinician speech into structured SOAP/DART records with hospital information system (HIS) integration, and aiGait, an AI gait and balance assessment tool powered by Fujitsu's Human Motion Analytics technology. Acer Medical also designs and sells medical hardware including the ARC-1000 non-mydriatic portable fundus camera and the VeriCompact APX-1 portable X-ray system, which uses Carbon Nanotube (CNT) cold-cathode technology to reduce radiation exposure to roughly one-quarter of conventional chest X-ray doses at a 3.2 kg weight.

The company monetizes through a hybrid model: subscription or license-based SaMD revenue for its AI imaging and voice software, bundled with installation, integration, and support services, alongside hardware sales of the ARC-1000 and VeriCompact devices. It sells primarily via direct enterprise sales to hospitals, clinics, and primary care networks (with a quote-based "Request a Demo" motion on its website) and supplements this with channel partners such as Upsynergy Taiwan and New Eye Inc. for Southeast Asian markets. The customer base spans ophthalmology and diabetes clinics, rehabilitation and long-term care facilities, sports science programs, and government-led telemedicine initiatives — exemplified by a five-hospital deployment in Phuket Province, Thailand. As of the latest disclosed figures, the company reports 300+ clinical implementations serving an estimated 350,000 patients annually, with 12 regulatory approvals secured across Taiwan (TFDA), Thailand (Thai FDA), Malaysia (MDA), Indonesia (MoH), Singapore (HSA), and the Philippines (FDA), and ISO 13485, ISO/IEC 27001, ISO/IEC 27701, and Taiwan QMS certifications underpinning its quality and information security posture.

Revenue is not publicly disclosed, and the company is internally financed through its parent Acer Group rather than external venture funding. Strategic direction is steered by Chairman Allen Lien (連加恩), and recent activity points to geographic expansion through the Phuket telemedicine partnership, vertical diversification via the Fujitsu/FIG senior wellness insurance app targeting roughly 30 million participants, and product breadth expansion through aiMed and aiGait alongside the imaging core.

Name

Acer Medical

Legal name

Acer Medical Inc.

Website

https://acer-medical.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Acer Medical is a Taipei-based Acer Group subsidiary that develops AI medical device software and hardware, including the VeriSee ophthalmology imaging suite, aiMed voice documentation, aiGait gait analysis, ARC-1000 fundus camera, and VeriCompact portable X-ray system, sold to hospitals, clinics, and government health programs across Taiwan and Southeast Asia.

Ownership category

akta.pro rank

Product category

AI Medical Device Software

NAICS

Ophthalmic Goods Manufacturing (339115), Surgical and Medical Instrument Manufacturing (339112), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)

SIC

Surgical & Medical Instruments & Apparatus (3841), Ophthalmic Goods (3851)

akta.pro primary industry

Radiology AI, CAD & Advanced Visualization Software (HLAHABAJ)

akta.pro secondary industry

Medical Imaging AI (HDAAAEAH)

Keywords

• AI medical imaging
• Ophthalmology diagnostics
• Bone density screening
• Medical device software
• Clinical AI solutions

Headquarters

HQ city

Taipei

HQ country

Taiwan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. AI Medical Device Software (VeriSee Suite): Acer Medical generates revenue through licensing of AI medical device software including VeriSee DR (diabetic retinopathy), VeriSee AMD (age-related macular degeneration), VeriSee GLC (glaucoma), and VeriOsteo OP (bone density). These are Software as a Medical Device (SaMD) products that require regulatory approval and are sold to healthcare institutions. Revenue is generated through software subscriptions or licenses with installation and support services. The company also provides integration services with hospital information systems.
2. Medical Hardware Devices: Acer Medical generates revenue from sales of medical hardware including the ARC-1000 non-mydriatic fundus camera and VeriCompact portable X-ray system. These devices are sold to healthcare facilities and may be bundled with AI software solutions. The company provides regulatory-approved medical devices that complement its software portfolio.
3. aiMed AI Voice Assistant Platform: The aiMed AI medical voice assistant is offered as a platform with enterprise features including dedicated system deployment, custom branding, and centralized account management. The product has different versions (standard and ultimate) with sub-account capabilities. Revenue is generated through subscription-based licensing with potential per-seat or enterprise pricing models.
4. aiGait Software License: aiGait gait analysis software is licensed to healthcare facilities, care centers, rehabilitation centers, and fitness facilities. The software is powered by Fujitsu's Human Motion Analytics technology. Revenue is generated through software licensing with subscription or perpetual license models.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

Acer Medical develops and sells AI-assisted diagnostic software (Software as a Medical Device) for diabetic retinopathy (VeriSee DR), age-related macular degeneration (VeriSee AMD), glaucoma (VeriSee GLC), and bone mineral density screening (VeriOsteo OP), along with a generative AI medical voice assistant (aiMed) and AI gait analysis software (aiGait). The company also manufactures medical hardware including the ARC-1000 non-mydriatic portable fundus camera and VeriCompact portable X-ray system. These solutions are sold primarily to hospitals, clinics, and primary care providers across Taiwan and Southeast Asia.

Product overview

Acer Medical offers a comprehensive AI-driven medical device portfolio built on a platform-plus-modules architecture. The core offerings include VeriSee DR (diabetic retinopathy), VeriSee AMD (age-related macular degeneration), VeriSee GLC (glaucoma), and VeriOsteo OP (bone mineral density) - all AI-assisted diagnostic screening software products powered by computer vision deep learning models. These are complemented by aiMed (generative AI medical voice assistant for clinical documentation), aiGait (AI-powered gait analysis), and hardware devices including ARC-1000 (portable fundus camera) and VeriCompact APX-1 (portable X-ray system). The VeriSee Platform provides centralized imaging analysis infrastructure. Products span ophthalmology, orthopedics, clinical documentation, and rehabilitation, with 300+ clinical implementations serving approximately 350,000 patients annually across 12 regulatory approvals globally.

Differentiator

Problem solved

Functional benefit

Products and services

• VeriSee DR AI-assisted diagnostic software that analyzes color fundus images from retinal cameras to detect diabetic retinopathy lesions (microaneurysms, hemorrhages, soft exudates, hard exudates) and recommend referral. Achieves 93% accuracy, 95% sensitivity, 90% specificity in clinical trial. Supports Topcon, Canon, Crystalvue, Nikon, and MiiS cameras.
• VeriSee AMD AI-assisted screening software for age-related macular degeneration that identifies high-risk AMD patients from fundus photographs. Provides results in 10 seconds with 95% accuracy, 90% sensitivity, and 96% specificity. First AI SaMD for AMD approved by Taiwan FDA.
• VeriSee GLC AI-assisted glaucoma suspect screening software that analyzes fundus images to detect glaucomatous signs including vertical cup-to-disc ratio (VCDR), rim-to-disc ratio (RDR), and retinal nerve fiber layer (RNFL) indicators. Provides recommendations in 10 seconds and integrates with HIS and PACS.
• VeriOsteo OP AI-assisted bone mineral density (BMD) abnormalities screening software that analyzes chest X-ray images (DICOM format) to predict BMD, calculate T-score, and output BMD abnormality recommendations. Achieves nearly 90% accuracy. Indicated for adults over 50 years old.
• aiMed Generative AI medical voice assistant platform that transforms real-time voice or text input into structured medical records (SOAP, DART format) with medical-grade transcription handling mixed-language conversations in noisy clinical environments. Includes HIS integration, dedicated deployment, custom branding, and centralized account management.
• aiGait AI-powered balance and gait assessment software that analyzes gait videos (e.g., TUG - Timed Up & Go) using Fujitsu's Human Motion Analytics technology. Extracts skeletal keypoints and generates objective metrics including gait speed, step length, cadence, sit-to-stand/turn times, with stability and variability analyses.
• ARC-1000 Non-mydriatic automated portable fundus camera with automatic 3D tracking and focusing for easy selfie-style image capture. No pupil dilation required, improving patient comfort and workflow. Compatible with VeriSee DR and VeriSee AMD diagnostic software.
• VeriCompact APX-1 Portable X-ray system weighing 3.2 kg with battery, utilizing advanced Carbon Nanotube (CNT) cold cathode X-ray tube technology. Delivers 1/4 of conventional chest X-ray radiation dose. Designed for chest and limb imaging with 14" x 17" exposure field at 100 cm.

Quantifiable outcome

• 93% screening accuracy for diabetic retinopathy with 95% sensitivity and 90% specificity in pivotal clinical trial
• +7 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration9 records

AI capability17 records

Feature8 records

Partnerships

Five partnerships are on record, tiered minor, core and flagship.

• Hangzhou Diagens BiotechnologyminorStrategic or Co-development Partner · 15 May 2026The Chinese University of Hong Kong signed a memorandum of understanding with Hangzhou Diagens Biotechnology to develop medical AI imaging for maternal and child healthcare in China's Greater Bay Area. While not a direct Acer Medical partnership, this represents an industry collaboration in the same medical AI imaging space where Acer Medical operates.
• New Eye Inc.coreStrategic or Co-development Partner · 7 May 2026Acer Medical partnered with Thailand-based New Eye Inc. and Upsynergy Taiwan to build an integrated AI healthcare ecosystem in Thailand, combining ophthalmic devices (ARC-1000 fundus camera), AI-assisted diagnostic systems (VeriSee DR/AMD/GLC), and telemedicine services. The collaboration secured regulatory approval from Thailand's Food and Drug Administration (TFDA) and a government-led telemedicine AI healthcare project in Phuket Province covering five hospitals. This partnership represents a significant milestone in Taiwan-Thailand smart healthcare cooperation and positions Acer Medical to expand its AI healthcare footprint across Southeast Asia.
• Upsynergy TaiwancoreChannel Partner/ Reseller/ Distributor · 7 May 2026Upsynergy Taiwan partnered with Acer Medical and New Eye Inc. (Thailand) to deploy integrated ophthalmology AI and telemedicine solutions across Thailand's healthcare system. The partnership has secured TFDA regulatory approval and a government-led telemedicine AI healthcare project in Phuket Province covering five hospitals. Upsynergy Taiwan serves as a key channel partner for Acer Medical's expansion into the Southeast Asian market.
• Fujitsu LimitedcoreTechnology or Integration · 24 October 2025Acer Medical collaborated with Fujitsu Limited and the International Gymnastics Federation (FIG) to develop a points-based health-promoting insurance concept featuring an AI-powered smartphone app that digitizes FIG's gymnastics program for seniors. The app uses Acer Medical's AI skeleton recognition technology combined with Fujitsu's Human Motion Analytics to analyze user movements, exercise form, muscle strength, and range of motion, converting assessments into points that can be used for insurance premium discounts. Field trial conducted October 23-24, 2025 at the 53rd Artistic Gymnastics World Championships in Jakarta with an initial target of approximately 30 million participants in FIG's Gymnastics for All program worldwide.
• International Gymnastics Federation (FIG)flagshipStrategic or Co-development Partner · 24 October 2025FIG partnered with Acer Medical and Fujitsu to develop an AI-powered health-promoting insurance concept that digitizes FIG's gymnastics program for seniors. The collaboration aims to leverage AI technology to track and reward physical activity, with the goal of promoting senior health and wellness. Initial target of approximately 30 million participants in FIG's Gymnastics for All program worldwide.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Emerging players

• VUNO: Korean medical AI company with cleared products in chest X-ray, fundus, and bone density analysis. VUNO's portfolio including AI fundus screening and BMD solutions makes it a comparable multi-modality medical AI player competing across several of Acer Medical's indications.
• Lunit: Korean medical AI company with FDA-cleared Lunit INSIGHT for chest X-ray and mammography analysis. It is comparable as an AI medical imaging company targeting radiology workflows, though its primary focus (chest/mammography) overlaps more with VeriOsteo OP than the retinal products.

Direct peers

• Eyenuk: Eyenuk's EyeArt is an FDA-cleared AI system for diabetic retinopathy screening, widely deployed in primary care. It directly competes with VeriSee DR in the AI retinal screening category and has similar accuracy and integration value proposition.
• Digital Diagnostics (IDx-DR): Digital Diagnostics developed IDx-DR, the first FDA-authorized autonomous AI diagnostic system for diabetic retinopathy. It is the most direct competitor to VeriSee DR in AI retinal screening, with overlapping clinical use case, regulatory pathway, and customer base (primary care, diabetes clinics).
• Aeye Health: Aeye Health develops AI-based retinal diagnostic solutions for diabetic retinopathy, AMD, and glaucoma screening. It competes directly with Acer Medical's VeriSee DR, VeriSee AMD, and VeriSee GLC products across similar ophthalmic indications.

Regional players

• Infervision: Chinese AI medical imaging company focused on radiology AI (chest CT, X-ray) deployed across China and select APAC markets. Comparable to Acer Medical as an APAC-focused medical AI imaging player with government hospital deployments, though serving different geographies.
• Deepwise: Chinese AI healthcare company offering AI-assisted diagnostic imaging (chest, brain, fundus) deployed in Chinese hospitals. Comparable to Acer Medical as an Asia-focused medical AI imaging platform with overlapping ophthalmology and radiology imaging offerings.

Broad incumbents

• Zebra Medical Vision (Nanox): Zebra Medical Vision (now part of Nanox) developed radiology AI algorithms for chest, bone, and other imaging. It is comparable as a broad radiology AI software company, particularly to VeriOsteo OP's chest X-ray BMD analysis use case.
• GE HealthCare: GE HealthCare acquired Digital Diagnostics (IDx) and offers broader imaging AI and ophthalmology solutions. As a broad incumbent, it competes indirectly with Acer Medical via larger hospital enterprise contracts and integrated imaging platforms that may bundle AI screening.
• Qure.ai: Qure.ai develops AI solutions for radiology imaging across chest, head, and musculoskeletal indications, with strong APAC and emerging-market presence. Comparable to Acer Medical in AI medical imaging targeting government screening programs and emerging-market healthcare systems.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/acer-medical

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Acer Medical